Ambrilia Biopharma Inc.: Ambrilia Announces Third Quarter 2006 Results and Provides Update on Lead Development Programs
14th Nov 2006, 14:16 GMT
MONTREAL, QUEBEC (MARKET WIRE) Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today its third quarter 2006 results, as well as the conversion of its 4,000,000 Series 1 First Preferred Share and provided an update on its lead development programs.
Ambrilia Biopharma Inc.: Ambrilia Announces Third Quarter 2006 Results and Provides Update on Lead Development Programs related news:
- DOR BioPharma, Inc.: DOR BioPharma Reports Third Quarter Financial Results, Reviews Recent Achievements — Market Wire - Medical and Healthcare
- DOR BioPharma Reports Third Quarter Financial Results, Reviews Recent Achievements — ArriveNet : Health
- Cytori Announces 3rd Quarter Results: Update on Adipose Stem Cells in Cardiac Disease and Reconstructive Surgery — RedOrbit News - Health
- BioSyent Inc. Announces Q3 Results: Sales Up 153% for the Qtr, 90% for 9 Months; Ytd Net Income $ 296,491 — ArriveNet : Health
- Alexza Reports Q3 Financial Results and Updates Status of Development Pipeline — StratWire - Business of Healthcare NewsFeed
- / CORRECTION - Rosetta Resources Announces Third Quarter 2006 Financial and Operating Results — ArriveNet : Press Releases
- CPAC, Inc.: CPAC, Inc. Announces Strong Second Quarter and Six-Month Results; Declares Dividend — Market Wire - Lifestyle and Leisure
- O2Diesel Announces Third Quarter 2006 Financial Results — ArriveNet : Autos
- China Biopharma Delivers 1.5 Million Doses Of Flu Vaccine In China — Health News from Medical News Today
- Flexible Solutions International, Inc.: FLEXIBLE SOLUTIONS Announces Third Quarter, 2006 Financial Results — Market Wire - Energy and Utilities
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech